Registration for a live webinar on 'Rare disease clinical trials: challenges and best practices' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- The hallmarks of cancer
- The hallmarks of cancer: the immune response
- Causes of cancer
- Tumors vs. the immune system
- Categories of cancer-associated antigens
- Non-viral cancers: vaccine targets (1)
- Non-viral cancers: vaccine targets (2)
- Human cancer viruses
- Persistent infection vaccine targets
- Trichodysplasia Spinulosa virus (TSV)
- Mutation prevalence in different human cancers
- Mutation-based targets for therapeutic vaccination
- The perspective of immunotherapeutics
- Approved cancer therapy immunologic reagents
- Clinical outcome predicted by immune response
- IMPACT study overall survival: final analysis
- Yervoy (ipilimumab)
- CTLA-4 & PD-1 blocking monoclonal antibodies (1)
- CTLA-4 & PD-1 blocking monoclonal antibodies (2)
- Clinical response patterns with ipilimumab
- Repeated MAGE-3 specific immunizations
- Virus-specific CTL adoptive transfer therapy
- Melanoma therapy: induction of autoimmune CTL
- Melanoma immunotherapy and depigmentation
- Immunotherapy of melanoma in cancer patients
- Autoimmune depigmentation in melanoma patients
Topics Covered
- The hallmarks of cancer
- Categories of cancer-associated antigens
- Viral & non-viral cancers: vaccine targets
- Immunotherapeutics
- Immunologic reagents approved for cancer therapy
- Clinical outcome based on immune response
- CTL-based therapy
- Virus-specific CTL adoptive transfer therapy
- Immunotherapy for Melanoma
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Melief, C. (2015, May 28). Cancer vaccines 1 [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 30, 2024, from https://doi.org/10.69645/DNXI1681.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Cornelis Melief, Consultant: I am CSO of ISA pharmaceuticals Stock Shareholder (self-managed): I have Stock Appreciation Rights in ISA pharmaceuticals
Cancer vaccines 1
Published on May 28, 2015
30 min
Other Talks in the Series: Immunotherapy of Cancer
Other Talks in the Series: Vaccines
Transcript
Please wait while the transcript is being prepared...
0:00
This lecture is about cancer vaccines.
And I'm Cornelis Melief,
Emeritus Professor at Leiden
University Medical Center
and Chief Scientific
Officer at ISA Pharmaceuticals.
0:16
This slide shows the major hallmarks
of cancer
published in the journal Cell in the year 2000.
And amazingly enough, of
all the properties here
of cancer cells, such as sustaining
proliferative signaling, evading
growth repressors, activating
invasion and metastasis, et cetera,
there is no mention at all
of the immune response against cancer cells.
Whereas we now know that this is
a major interaction taking
place between cancer cells
and the immune system.
0:57
Fortunately, Hanahan and Weinberg
realized this and revisited
the hallmarks of cancer yet
again in a publication in Cell
in the year 2011.
And now at the right-hand
side of this slide,
you see emerging
hallmarks, enabling
characteristics, two of which
deal with the immune system.
So in order for cancer
to be successful,
it has to avoid immune destruction.
On the other hand, the other side
of the coin of the immune system
is that certain types of
immunity, such as inflammation
of a particular type, for example,
that promoted by interleukin-6,
can promote tumor growth rather than
kill tumor cells, whereas avoiding
immune destruction means that
there are types of immune response
that we will return to that
can actually kill tumor
cells, such as cytotoxic T cells
and interferon gamma-producing T cells, in general.